Podcast: TRK fusion-positive GI cancers
Podcast: TRK fusion-positive GI cancers
Prof. Frédérique Penault-Llorca, Prof. Andrea Sartore-Bianchi
In this NTRK CONNECT podcast Prof Frédérique Penault-Llorca and Prof Andrea Sartore-Bianchi discuss the detection and management of TRK fusion-positive GI cancers.Prof. Frédérique Penault-Llorca
Pathologist
University of Clermont-Ferrand
France
Frédérique PENAULT-LLORCA, MD, PhD, graduated as a medical specialist in pathology in 1993 and in oncology in 1995. Also, in 1995, she received a PhD from the Université d’Aix-Marseille II in cellular biology and microbiology, on the topic of HER2. Professor PENAULT-LLORCA is currently professor of Pathology at the University of Clermont-Ferrand, CEO of the Comprehensive Regional Cancer Institute Centre Jean PERRIN, deputy director of the research team INSERM 1240 IMoST, and head of the Molecular Biology Plateform at Centre Jean Perrin, Clermont-Ferrand, France, and Vice-President of UNICANCER GROUP. She chairs the Immuno- Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies (ESMO, ASCO, ECP, AIP, SFP. Her main areas of interest as a pathology being female cancers. Professor PENAULT-LLORCA has conducted various biomarkers-based research studies in breast, ovarian, colorectal, gastric, and lung cancer in relation to response to targeted therapies and immunotherapies. She also acts as a coordinating pathologist for various oncology trials. Professor PENAULT-LLORCA has written more than 440 peer-reviewed publications and several books on female cancers and biomarker testing methods and issues.
Prof. Frédérique Penault-Llorca has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Bayer and Roche.
Prof. Andrea Sartore-Bianchi
Medical Oncologist
Niguarda Cancer Center
Italy
Dr Andrea Sartore-Bianchi is head of Clinical Molecular Oncology at the Department of Hematology & Oncology, Niguarda Cancer Center, Milano, Italy. He completed his medical degree at the University of Pavia in 1999, and undertook specialist training at IRCCS Policlinico San Matteo. After completing his doctoral studies, he conducted preclinical research at the Division of Clinical Pharmacology and Experimental Cancer Therapeutics in the Department of Medicine at Brown University, Rhode Island, USA. Dr Sartore-Bianchi’s main clinical and research interests include the treatment of gastrointestinal cancers, particularly colorectal carcinomas, focusing on biomarkers of sensitivity/resistance to molecular-targeted therapies and on the epidermal growth factor receptor signal transduction pathway. He is principal and co-investigator in Phase I-II-III clinical trials for gastrointestinal malignancies, and first author of research articles in the Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research and PLoS One. Currently, he is adjunct Professor for the School of Specialization in Oncology and Pharmacology at the University of Milano. He has been listed among the top 30 authors of primary research papers on cancer.
Prof. Andrea Sartore-Bianchi has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Amgen, Bayer, Sanofi and Servier Pharmaceuticals.
Podcast |
20 min
|
Oct 2021
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
In the GI episode, Prof Frédérique Penault-Llorca and Prof Andrea Sartore-Bianchi provide a summary and share their personal experiences about the diagnosis and treatment of TRK fusion-positive GI cancer.
Prof Sartore-Bianchi provides an overview of NTRK genes and the biology of NTRK fusions, including their role as a driver of oncogenesis. He then provides a concise summary of the approved TRK inhibitor therapies, larotrectinib and entrectinib, emphasising the expanding dataset showing high response rates and durable responses seen in patients with GI cancers.
Prof Penault-Llorca outlines the challenges pathologists face detecting the extremely rare NTRK fusions in GI cancers, providing a summary of the range of tools available to detect them and offering her perspectives on an enrichment strategy for GI cancers, especially colorectal cancer.
They conclude by emphasising the importance of not missing any patients, through applying enrichment strategies that can enhance the likelihood of finding NTRK fusions. In doing so, more patients will be able to benefit from the proven efficacy of TRK inhibitor therapy.
Podcast Transcript
Frédérique Penault-Llorca
Today, with Andrea we are going to go through the diagnosis and treatment of NTRK fusion-positive GI cancers. Andrea, what are the NTRK genes, and what about the NTRK fusion; why are they so interesting to look at in GI cancers?
Andrea Sartore-Bianchi
Yes, thank you Frédérique, and indeed we know the gene fusions can be a driver of oncogenesis, but it is now when we are seeing very important advances in clinical sequencing technologies that we are aware of new…
This programme is supported by an Independent Educational Grant from Bayer
PRECISION ONCOLOGY CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca and Bayer.